Skip to main content
x
Norris Cotton Cancer Center
In This Section
 
Randomized Trial Of Standard Chemotherapy Alone Or Combined With Atezolizumab As Adjuvant Therapy For Patients With Stage III Colon Cancer And Deficient DNA Mismatch Repair
Principal Investigator (?)
Study Number
A021502
Summary
This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body''s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer. 
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Lebanon,Manchester,Nashua

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.

0